Influx Health.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0MYZ01012
  • NSEID: INFLUX
  • BSEID:
INR
202.55
-6.1 (-2.92%)
BSENSE

Feb 24

BSE+NSE Vol: 37800

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

37.8 k (112.84%) Volume

Shareholding (Sep 2025)

FII

1.83%

Held by 7 FIIs

DII

6.76%

Held by 1 DIIs

Promoter

73.53%

How has been the historical performance of Influx Health.?

13-Nov-2025

Influx Health showed positive financial performance from March 2024 to March 2025, with net sales increasing from 99.97 Cr to 104.85 Cr, operating profit rising from 16.96 Cr to 20.56 Cr, and profit after tax growing from 11.13 Cr to 13.37 Cr, despite a decrease in cash flow from operating activities. Total assets and liabilities both grew significantly, indicating balanced growth.

Answer:<BR>The historical performance of Influx Health shows a positive trend in key financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Influx Health's net sales increased from 99.97 Cr in March 2024 to 104.85 Cr in March 2025, reflecting a growth in total operating income from 99.97 Cr to 104.85 Cr. The raw material cost decreased slightly from 65.27 Cr to 63.41 Cr, while employee costs rose from 7.04 Cr to 8.79 Cr. Total expenditure, excluding depreciation, increased from 83.01 Cr to 84.29 Cr. Operating profit (PBDIT) rose from 16.96 Cr to 20.56 Cr, leading to an operating profit margin improvement from 16.97% to 19.61%. Profit before tax also increased from 14.93 Cr to 17.88 Cr, with profit after tax rising from 11.13 Cr to 13.37 Cr, resulting in a PAT margin increase from 11.13% to 12.75%. The company's total assets grew significantly from 40.82 Cr to 70.12 Cr, while total liabilities increased from 40.82 Cr to 70.12 Cr, indicating a balanced growth in both assets and liabilities. Cash flow from operating activities decreased from 8.00 Cr to 7.00 Cr, contributing to a net cash outflow of 1.00 Cr in March 2025, compared to no outflow in the previous year. Overall, Influx Health demonstrated a strong performance with improvements in profitability and asset growth.

View full answer

Is Influx Health. overvalued or undervalued?

04-Dec-2025

As of December 3, 2025, Influx Health is fairly valued with a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%, positioning it between peers Sun Pharma and Divi's Lab in terms of valuation.

As of 3 December 2025, Influx Health has moved from an attractive to a fair valuation grade. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 40.22, an EV to EBITDA of 24.18, and a ROCE of 33.05%. <BR><BR>In comparison to peers, Influx Health's PE ratio is higher than Sun Pharma's 37.51 and significantly lower than Divi's Lab's 68.92, which is categorized as very expensive. While the company has shown strong returns over the past week and month, outperforming the Sensex, its current valuation suggests that it is neither undervalued nor overvalued in the current market context.

View full answer

Why is Influx Healthtech Ltd falling/rising?

21-Feb-2026

As of 20-Feb, Influx Healthtech Ltd's stock price is at 215.00, up 1.63% today and showing a positive trend over the past month with a 13.37% gain. Despite recent volatility and decreased investor participation, the stock's performance remains strong compared to longer-term moving averages.

As of 20-Feb, Influx Healthtech Ltd's stock price is rising, currently at 215.00, reflecting an increase of 3.45 (1.63%). This rise is notable as the stock has outperformed its sector by 1.44% today. Despite a recent decline of 6.36% over the past week, the stock has shown a positive trend over the past month with a gain of 13.37%. <BR><BR>The current price is higher than the 100-day and 200-day moving averages, indicating a strong performance in the longer term, although it remains lower than the shorter-term moving averages of 5-day, 20-day, and 50-day. This suggests that while there may be some volatility in the short term, the overall trend is positive. <BR><BR>However, it is important to note that there has been a decrease in investor participation, with delivery volume falling by 7.08% compared to the 5-day average. Despite this, the stock remains liquid enough for trading, which may contribute to the current upward movement in price. Overall, the combination of recent positive performance and market conditions appears to be driving the stock's rise.

View full answer

Which are the latest news on Influx Health.?

24-Feb-2026

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 482 Cr (Micro Cap)

stock-summary
P/E

36.00

stock-summary
Industry P/E

32

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.41

stock-summary
Return on Equity

14.71%

stock-summary
Price to Book

5.37

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.04%
0%
-5.04%
6 Months
37.84%
0%
37.84%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Influx Health. for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
4.90%
EBIT Growth (5y)
17.41%
EBIT to Interest (avg)
16.43
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.05
Sales to Capital Employed (avg)
1.16
Tax Ratio
25.07%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
8.67%
ROCE (avg)
33.05%
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
36
Industry P/E
0
Price to Book Value
5.26
EV to EBIT
24.68
EV to EBITDA
21.29
EV to Capital Employed
8.16
EV to Sales
4.18
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
33.05%
ROE (Latest)
14.71%

Technicals key factors

Indicator
Weekly
Monthly
Icon
No records
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 7 FIIs (1.83%)

Promoter with highest holding

Munir Abdul Ganee Chandniwala (69.73%)

Highest Public shareholder

Ccv Emerging Opportunities Fund-i (2.31%)

Individual Investors Holdings

13.92%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Influx Health."
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "alert": "No Half Yearly Results declared by Influx Health."
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Influx Health."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "alert": "No Annual Results declared by Influx Health."
  }
]
stock-summaryCompany CV
About Influx Healthtech Ltd stock-summary
stock-summary
Influx Healthtech Ltd
Micro Cap
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available